Adjuvant Everolimus Falls Short in High-Risk Kidney Cancer
However, the drug did show benefit in a subgroup at highest risk of recurrence after nephrectomy
Source: medpagetoday.com
Stay updated with breaking news from Axel Bex. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
However, the drug did show benefit in a subgroup at highest risk of recurrence after nephrectomy
Studies appear to contradict benefit previously shown with pembrolizumab in this setting
Manalapan, N.J. (PRWEB) August 29, 2022 -- Mashup Media, LLC, in partnership with Drs. Thomas Powles and Brian Rini of The Uromigos, is pleased to announce